Brandon Young has 20 years of experience utilizing technology to improve testing and detection of genetic variation in human diseases. He was one of the early laboratory pioneers in microarray and gene sequencing projects in startup companies and large academic institutions. He has extensive experience in research, set-up, operations, configuration and P&L of running genomics labs. He has provided data and analysis for multiple national and international clinical trials.
Brandon has helped design, build and run labs for a number of prestigious centers throughout the US, including Scripps Florida, Human Longevity Institute (HLI), and Avera McKennan. His current work with the Darwin Foundation is providing next generation sequencing services to support groundbreaking clinical studies for the WIN consortium, focusing on personalized precision oncology testing and treatment protocols. This early stage work is generating over 50% improvements in clinical outcomes for participating cancer patients.
Deepankar Roy is a trained research scientist and has worked on several cell line engineering platform technologies at Larix Bioscience and Genentech. Prior to these roles, he was a postdoctoral fellow at Genentech’s Research Oncology division where he studied cancer signaling pathways. Deepankar completed his doctoral studies in Biochemistry and Molecular Biology at University of Southern California where he undertook a reductionist approach in studying nucleic acid behavior in mammalian immune systems.
He has worked with early stage life science companies as Director of Business and Scientific Operations at Venomyx Inc., an antivenom therapeutics startup and as the Director of Business/Product Development at Colby Pharmaceutical Company and its subsidiary CancerVacs Inc, companies involved in development of immunotherapeutics for allergy, cancer and other diseases.
Jay Goth is the Managing Partner of Forentis Fund, a biotech venture capital firm focused on precision medicine. He is a veteran entrepreneur, with experience in the hospitality, energy, finance and technology verticals. As a founding executive of Commonwealth Energy, Jay helped the company go from start-up to almost $500 million in revenues in five years, becoming the largest unregulated supplier of electricity and natural gas in the country when the company went public on the AMEX.
He serves as Executive Director of InSoCal CONNECT, a nonprofit that has structured mentorship and training programs for entrepreneurs, was a Senior Consultant with TriTech SBDC, one of seven technology designated Small Business Development Centers operating under the SBA, and served as an Entrepreneur in Residence at the University of California Riverside. Jay also serves on the board of directors for Credence Code Technologies, Inc., a company focused on blockchain development and implementation. He also serves on the board of Burble, a company that delivers the power of story through minimally defined immersive environments. Jay is on the board of directors for InSoCal CONNECT and Reach Out, nonprofits dedicated to improving lives in the Inland Empire.
John Powers spent 22 years in the wireless industry driving acceptance and adoption of new technologies. His background in wireless convergence, and cloud computing is complimentary to the goals of the medical industry, especially in integrating the large amount of genetic/genomic data into everyday medicine.
As CEO of IntraOp Medical, John worked with multiple discipline teams including physicists, surgeons, radiation and medical oncologists in the top cancer centers around the world. Working with the Centers for Medicare & Medicaid Services (CMS) John was able to secure a new reimbursement code and reimbursement for Intra-Operative Radiation Therapy (IORT). He more than tripled IntraOp’s installed customer base, making the company profitable in 2012, followed by a take private restructuring and change of ownership.
We are assembling a dynamic and dedicated group of advisory board members to provide guidance and insight to our incubator companies. We will be updating this area soon.
We have established a number of partnerships with like-minded organizations from around the world. Here is a list of some of the organizations that we are working with:
It is estimated that one in seventeen people are born with or develop a rare disease during their lifetime. At least 80% of rare diseases have an identified genetic component, with 50% of new cases of rare diseases being identified in children. However, it can take considerable time and expense between a patient first presenting at a doctors and receiving an accurate diagnosis. The time taken to sequence a whole human genome has been dramatically reduced and will become more affordable for routine use as the price continues to fall.
Genomics England is a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer. Genomics is made up of many moving parts − from the understanding and consent of the public, to truly pioneering research, to building an effective NHS infrastructure. The Discovery Forum and the industry partnerships it builds are every bit as important to the success of genomic medicine.
The Global Alliance for Genomics and Health (GA4GH) is an international, nonprofit alliance formed in 2013 to accelerate the potential of research and medicine to advance human health. Bringing together 500+ leading organizations working in healthcare, research, patient advocacy, life science, and information technology, the GA4GH community is working together to create frameworks and standards to enable the responsible, voluntary, and secure sharing of genomic and health-related data. All of our work builds upon the Framework for Responsible Sharing of Genomic and Health-Related Data.
GA4GH Connect is a five-year strategic plan that aims to drive uptake of standards and frameworks for genomic data sharing within the research and healthcare communities in order to enable responsible sharing of clinical-grade genomic data by 2022. GA4GH Connect links our Work Streams with Driver Projects—real-world genomic data initiatives that help guide our development efforts and pilot our tools.
Southern California Biomedical Council (SoCalBio) is a nonprofit, member-supported trade association that serves the biotech, med tech, IVD and digital health communities in the six counties that comprise the Greater Los Angeles region (Los Angeles, Orange, Ventura, Santa Barbara, Riverside and San Bernardino). SoCalBio’s programs help local firms gain access to capital, potential partners, and other business services. The Council also promotes technology transfer and workforce training, while informing policymakers and the public at-large about the benefits of the region’s bioscience industry. SoCalBio is open to membership by firms and organizations engaged in all aspects of bioscience research, technology development, and commercialization. All of the incubator companies at Murrieta Genomics receive a complimentary membership to SoCalBio.
Hello Tomorrow is a non-profit organisation bringing together a community of actors aiming to unlock the potential of deep technologies to solve the world’s toughest challenges. We source deeptech projects and startups and facilitate collaboration between entrepreneurs, industries and investors in order to propel innovation from the lab to the market.
Hello Tomorrow organizes startup competitions, mentorship programs and a series of events around the world, as well as educating and consulting relevant stakeholders on emergence of deep technologies. Hello Tomorrow is fast becoming a key reference platform in deeptech innovation and entrepreneurship.